CathVision raises €13m funding to begin multi-center clinical studies

– DENMARK, Copenhagen –  CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, has completed an investment round of a total of 13M euro. Both existing and new investors participated in the round. The proceeds allow the company to begin multi-center clinical studies and complete its FDA approval process for the CathVision Cube system and associated software algorithms.

“We are excited to finalize the testing needed for FDA clearance and CE marking, and we expect physicians to acquire clinical data from our system later this year,” said CEO Mads Emil Matthiesen. “Our organization has grown rapidly with the recent addition of a dedicated software team that allows us to continue to focus on enabling the EP cardiologists to succeed in cardiac ablation for a number of different cardiac arrhythmias”.

“This oversubscribed and significant financing round took place in a challenging funding environment for MedTech companies and it is a clear testimony to the progress we have made over the years in honing our unique technology position in cardiac ablation,” said CFO Rune Ørndrup.

“CathVision is relentlessly delivering on its strategic goal set as the company continues to evolve from a small start-up company to an established cardiology innovator with a strong management team, inhouse product development, clinical operations, and commercialization. We are thankful for the investor confidence shown us in this round” said Board Chairman Søren Thestrup-Nielsen.

“CathVision has a strong product and works in one of the fastest-growing segments of medical technology. Furthermore, CathVision has worked patiently and persistently with its technology for a number of years, and we have been following and continually invested in the company. We strongly believe that Cathvision can become an important player within the industry and that is the reason why we participate in this round,” said Tonni Bülow-Nielsen, Managing Partner in Vaekstfonden’s department of direct investments VF Venture.

About CathVision

Headquartered in Copenhagen, Denmark with its US business office in Minnesota USA, CathVision is developing and selling medical devices to treat cardiac arrhythmias. The solutions are centered on an innovative electrophysiology system to provide exceptional EP signals for the identification and characterization of arrhythmias.

For more information: https://cathvision.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.